Table 3 Summary of treatment regimens prior and following the development of monocytosis and the clinical status of patients
Case | Age/Sex | Treatment | Clinical status | Cause of death | |
|---|---|---|---|---|---|
Pre-monocytosis | Post-monocytosis | Post-monocytosis | |||
1 | 74/M | None | Gleevec, anagrelide, hydroxyurea, decitabine | Dead | Respiratory and renal failure |
2 | 66/F | Thalidomide | Panibinostat | Supportive care, transfusion dependent | — |
3 | 69/M | Not available | Not available | Alive | — |
4 | 52/F | Lestaurtinib, thalidomide, arsenic/ara C | Stem cell transplant | Dead (acute myeloid leukemia) | Acute myeloid leukemia |
5 | 67/M | Darbopetin alfa, danazol | Thalidomide, prednisone, decitabine, lestaurtinib arsenic/ara C, hydroxyurea, interferon | Dead | Respiratory failure |
6 | 82/F | None | Pomalidomide, prednisone, ruxolitinib, hydroxyurea | Dead | Unknown |
7 | 62/F | Hydroxyurea, anagrelide | Hydroxyurea, interferon | Stable disease | — |
8 | 79/M | Hydroxyurea | Hydroxyurea | Dead | Unknown |
9 | 76/M | Hydroxyurea, anagrelide | Hydroxyurea and anagrelide | Transfusion dependent | — |
10 | 63/F | Interferon | Interferon | Stable disease | — |
